Antibody blockade of CD96 by distinct molecular mechanisms

References

• Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006;90:297–8. doi:10.1016/S0065-2776(06)90008-X.
   PubMed Web of Science ®Google Scholar
• Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44:989–1004. doi:10.1016/j.immuni.2016.05.001.
   PubMed Web of Science ®Google Scholar
• Rotte A, Jin JY, Lemaire V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol. 2018;29:71–83. doi:10.1093/annonc/mdx686.
   PubMed Web of Science ®Google Scholar
• Manieri NA, Chiang EY, Grogan JLTIGIT, Key A. Inhibitor of the cancer immunity cycle. Trends Immunol. 2017;38:20–28. doi:10.1016/j.it.2016.10.002.
   PubMed Web of Science ®Google Scholar
• Dougall WC, Kurtulus S, Smyth MJ, Anderson AC. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev. 2017;276:112–20. doi:10.1111/imr.12518.
   PubMed Web of Science ®Google Scholar
• Jin HS, Park Y. Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy. BMB Rep. 2021;54:2–11. doi:10.5483/BMBRep.2021.54.1.229.
   PubMed Web of Science ®Google Scholar
• Chan CJ, Martinet L, Gilfillan S, Souza-Fonseca-Guimaraes F, Chow MT, Town L, Ritchie DS, Colonna M, Andrews DM, Smyth MJ. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol. 2014;15:431–38. doi:10.1038/ni.2850.
   PubMed Web of Science ®Google Scholar
• Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, Park S, Javinal V, Chiu H, Irving B, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014;26:923–37. doi:10.1016/j.ccell.2014.10.018.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Paniccia A, Schulick AC, Chen W, Koenig MR, Byers JT, Yao S, Bevers S, Edil BH. Identification of CD112R as a novel checkpoint for human T cells. J Exp Med. 2016;213:167–76. doi:10.1084/jem.20150785.
   PubMed Web of Science ®Google Scholar
• Chiang EY, de Almeida PE, de Almeida Nagata DE, Bowles KH, Du X, Chitre AS, Banta KL, Kwon Y, McKenzie B, Mittman S, et al. CD96 functions as a co-stimulatory receptor to enhance CD8(+) T cell activation and effector responses. Eur J Immunol. 2020;50:891–902. doi:10.1002/eji.201948405.
   PubMed Web of Science ®Google Scholar
• Johnston RJ J, Lee PSs L, Strop P, Smyth MJ S. Cancer immunotherapy and the Nectin family. Annual Rev Cancer Biol. 2021;5:203–19. doi:10.1146/annurev-cancerbio-060920-084910
   Google Scholar
• Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10:48–57. doi:10.1038/ni.1674.
   PubMed Web of Science ®Google Scholar
• Holmes VM, Maluquer de Motes C, Pt R, Roldan J, Ak B, JS O, Krummenacher C. Interaction between nectin-1 and the human natural killer cell receptor CD96. PLoS One. 2019;14:e0212443. doi:10.1371/journal.pone.0212443.
   PubMed Web of Science ®Google Scholar
• Liu J, Qian X, Chen Z, Xu X, Gao F, Zhang S, Zhang R, Qi J, Gao GF, Yan J. Crystal structure of cell adhesion molecule nectin-2/CD112 and its binding to immune receptor DNAM-1/CD226. J Immunol. 2012;188:5511–20. doi:10.4049/jimmunol.1200324.
   PubMed Web of Science ®Google Scholar
• Harrison OJ, Vendome J, Brasch J, Jin X, Hong S, Katsamba PS, Ahlsen G, Troyanovsky RB, Troyanovsky SM, Honig B, et al. Nectin ectodomain structures reveal a canonical adhesive interface. Nat Struct Mol Biol. 2012;19:906–15. doi:10.1038/nsmb.2366.
   PubMed Web of Science ®Google Scholar
• Samanta D, Ramagopal UA, Rubinstein R, Vigdorovich V, Nathenson SG, Almo SC. Structure of Nectin-2 reveals determinants of homophilic and heterophilic interactions that control cell-cell adhesion. Proc Natl Acad Sci U S A. 2012;109:14836–40. doi:10.1073/pnas.1212912109.
   PubMed Web of Science ®Google Scholar
• Deuss FA, Watson GM, Fu Z, Rossjohn J, Berry R. Structural basis for CD96 immune receptor recognition of Nectin-like protein-5, CD155. Structure. 2019;27:219–28 e3. doi:10.1016/j.str.2018.10.023.
   PubMed Web of Science ®Google Scholar
• Deuss FA, Watson GM, Goodall KJ, Leece I, Chatterjee S, Fu Z, Thaysen-Andersen M, Andrews DM, Rossjohn J, Berry R. Structural basis for the recognition of nectin-like protein-5 by the human-activating immune receptor, DNAM-1. J Biol Chem. 2019;294:12534–46. doi:10.1074/jbc.RA119.009261.
   PubMed Web of Science ®Google Scholar
• Stengel KF, Harden-Bowles K, Yu X, Rouge L, Yin J, Comps-Agrar L, Wiesmann C, Bazan JF, Eaton DL, Grogan JL. Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering. Proc Natl Acad Sci U S A. 2012;109:5399–404. doi:10.1073/pnas.1120606109.
   PubMed Web of Science ®Google Scholar
• Deuss FA, Gully BS, Rossjohn J, Berry R. Recognition of nectin-2 by the natural killer cell receptor T cell immunoglobulin and ITIM domain (TIGIT). J Biol Chem. 2017;292:11413–22. doi:10.1074/jbc.M117.786483.
   PubMed Web of Science ®Google Scholar
• Barbey-Martin C, Gigant B, Bizebard T, Calder LJ, Wharton SA, Skehel JJ, Knossow M. An antibody that prevents the hemagglutinin low pH fusogenic transition. Virology. 2002;294:70–74. doi:10.1006/viro.2001.1320.
   PubMed Web of Science ®Google Scholar
• Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E, De La Pena AT, Cupo A, Julien JP, van Gils M, Lee PS, et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity. 2014;40:669–80. doi:10.1016/j.immuni.2014.04.008.
   PubMed Web of Science ®Google Scholar
• Wang F, Tsai JC, Davis JH, Chau B, Dong J, West SM, Hogan JM, Wheeler ML, Bee C, Morishige W, et al. Design and characterization of mouse IgG1 and IgG2a bispecific antibodies for use in syngeneic models. MAbs. 2020;12:1685350. doi:10.1080/19420862.2019.1685350.
   PubMed Web of Science ®Google Scholar
• Vonrhein C, Flensburg C, Keller P, Sharff A, Smart O, Paciorek W, Womack T, Bricogne G. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr D Biol Crystallogr. 2011;67:293–302. doi:10.1107/S0907444911007773.
   PubMed Web of Science ®Google Scholar
• Kabsch W. XDS. Acta Crystallogr D Biol Crystallogr. 2010;66:125–32. doi: 10.1107/S0907444909047337.
   PubMedGoogle Scholar
• Evans P. Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr. 2006;62:72–82. doi:10.1107/S0907444905036693.
   PubMed Web of Science ®Google Scholar
• Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AG, McCoy A, et al. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr. 2011;67:235–42. doi:10.1107/S0907444910045749.
   PubMed Web of Science ®Google Scholar
• Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010;66:486–501. doi:10.1107/S0907444910007493.
   PubMed Web of Science ®Google Scholar
• Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010;66:213–21. doi:10.1107/S0907444909052925.
   PubMed Web of Science ®Google Scholar
• Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr. 2010;66:12–21. doi:10.1107/S0907444909042073.
   PubMed Web of Science ®Google Scholar